Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J
Department of Medicine, Durham Veterans Administration Medical Center, North Carolina 27705.
J Infect Dis. 1988 Feb;157(2):332-7. doi: 10.1093/infdis/157.2.332.
Hepatitis B remains a significant risk to patients receiving chronic hemodialysis, but no certain method of prevention has been identified. We tested two vaccines, plasma-derived vaccine (40-micrograms dose) and recombinant-derived vaccine (40-micrograms and 20-micrograms doses), in 61 patients with chronic renal failure who were not yet dependent on dialysis. Patients were followed up clinically and with laboratory tests of kidney function and hepatitis B virus serology for one year. Significantly more recipients of plasma-derived vaccine responded to vaccination; they also achieved a higher titer of antibody to hepatitis B virus than did recipients of recombinant-derived vaccine when evaluated at 6, 7, 9, and 12 mo after vaccination. No serious side effects were observed with any vaccine preparation, nor were excessive adverse effects observed in any group. Compared with the dialysis patients previously studied, patients with renal failure who were not yet dependent on dialysis responded more favorably to the hepatitis B virus vaccine.
乙肝对于接受慢性血液透析的患者来说仍然是一个重大风险，但尚未确定确切的预防方法。我们对61例尚未依赖透析的慢性肾衰竭患者测试了两种疫苗，即血浆源性疫苗（40微克剂量）和重组源性疫苗（40微克和20微克剂量）。对患者进行了为期一年的临床随访以及肾功能和乙肝病毒血清学实验室检查。接受血浆源性疫苗的接种者产生疫苗应答的比例显著更高；在接种后6、7、9和12个月进行评估时，他们产生的乙肝病毒抗体滴度也高于接受重组源性疫苗的接种者。未观察到任何疫苗制剂有严重副作用，也未在任何组中观察到过多的不良反应。与之前研究的透析患者相比，尚未依赖透析的肾衰竭患者对乙肝病毒疫苗的反应更好。
